Introduction
============

One of the difficulties of evaluating the safety of new medications for chronic obstructive pulmonary disease (COPD) is the high prevalence of comorbid conditions. A recent study of Medicare beneficiaries in the US found that 32.7% of COPD patients had at least one other major chronic illness, and 39.0% had two or more.[@b1-copd-8-127] Although COPD is among the leading causes of death worldwide, few published data are available on the incidence and prevalence of specific comorbid illnesses, particularly renal and hepatic disease. COPD patients with known renal or hepatic disease are often excluded from clinical trials, and those who are found to have undiagnosed asymptomatic elevations in renal function tests or hepatic transaminases during screening are also usually excluded. Therefore, the post-marketing surveillance for treatment safety among COPD patients in the general population is problematic because of the lack of epidemiology on the prevalence of renal and hepatic disease.

Further complicating the mission of monitoring new drug safety is the fact that COPD patients are more likely than non-COPD patients to take a variety of prescription medications. In one survey, we found that COPD patients used approximately 50% more cardiovascular agents than age-matched and gender-matched controls, and almost twice as many antibiotics, analgesics, and psychotherapeutics.[@b2-copd-8-127]

The purpose of this project is to describe the prevalence of renal and hepatic diseases and related laboratory abnormalities in a population-based cohort of COPD patients and compare these rates with age-matched and gender-matched controls. We also describe the utilization of potentially renotoxic or hepatotoxic prescription drugs in these cohorts.

Materials and methods
=====================

Study site
----------

This study was conducted among members of the Lovelace Health Plan (LHP), a regional health insurance company that provides a range of commercial employer-sponsored, health maintenance organization, preferred provider organization, and Medicare or Medicaid managed care products. The LHP is a component of Lovelace Health Systems, an integrated medical system based in Albuquerque, NM, USA, which includes four hospitals and a network of outpatient clinics. The LHP served approximately 240,000 members annually during the study period (2005--2008). Most LHP clients, as ascertained by self-report on annual surveys during the study period, live in urban areas, and 38.7% are Hispanic, 55.8% are non-Hispanic white, 2.1% are Native American, and 3.4% are other racial designations.

Study subjects
--------------

The COPD patients identified for this study had to meet each of the following criteria: be aged 40 years or older at the start of the study period; have at least two outpatient visits on separate days or at least one hospitalization associated with an ICD-9 code consistent with COPD \[491.x (chronic bronchitis); 492.x (emphysema); or 496 (COPD)\]; and be continuously enrolled in the LHP for at least 12 months during the 3-year study period. We have shown this system for identifying COPD patients to be more than 95% accurate in two previous projects using the LHP database.[@b3-copd-8-127],[@b4-copd-8-127] Patients aged 90 years or older at the beginning of the study period, or who could not be matched to at least one individual without COPD by age and gender, were excluded. Those diagnosed with alpha-1 antitrypsin deficiency were also excluded. The control group was created by randomly selecting for each COPD patient up to three LHP members of the same age and gender who did not have any diagnosis of COPD, but had a similar duration of enrollment (± 2 months). This project was approved and supervised by the institutional review board for Lovelace Health Systems.

Capture of renal and hepatic diagnoses
--------------------------------------

To identify diagnosed renal and hepatic diseases in the COPD and control cohorts, we surveyed the database for any utilization associated with an ICD-9 code consistent with renal or urinary tract disease (580.x--599.x) or hepatobiliary/pancreatic disease (070.x, 570.x--577.x). Patients were required to have the same renal or hepatic disease code on two outpatient visits on separate days, or during one hospitalization, to avoid the problem of "rule-out" diagnoses.

Capture of nephrotoxic and hepatotoxic drugs
--------------------------------------------

All medications dispensed to patients in either the COPD or control populations during the study period were captured. Drugs were identified as being potentially nephrotoxic or hepatotoxic if these precautions were listed as common or potentially serious side effects for these agents as included in their monograph in the Physicians' Desk Reference.[@b5-copd-8-127]

Stratification of COPD by complexity
------------------------------------

One of the secondary aims of this project was to see whether there was an association between COPD severity and the prevalence of hepatic or renal laboratory abnormalities. We were also interested in whether utilization of potentially nephrotoxic or hepatotoxic medications increased with COPD complexity. Spirometry results are not included in the LHP database, so we used a classification method that stratifies COPD patients by their COPD-related health care utilization.[@b6-copd-8-127] Patients who were admitted to the hospital primarily for complications of COPD, or who had ≥20 outpatient encounters for COPD during the study period, were designated high complexity. Patients who had between five and 19 outpatient encounters for COPD but were never admitted to the hospital were designated as moderate complexity. The rest of the COPD patients in the cohort were designated as low complexity. This system divided the COPD cohort into three relatively equal groups. We have found in our previous work in this cohort that COPD utilization was a significant but weak correlate with the degree of airflow obstruction, although increased utilization was in fact a better predictor of poor clinical outcomes.[@b4-copd-8-127]

Statistical analysis
--------------------

The McNemar test for paired proportions was used to compare COPD case and non-COPD control cohorts for differences in renal and hepatobiliary diagnoses. Laboratory abnormalities were compared using the Chi-square test. The Wilcoxon rank-sum test was used to compare mean prescription fills. A *P* value of 0.05 or less was designated as statistically significant. All data processing and computations were performed using SAS^®^ statistical software (SAS Institute Inc, Windows Desktop version 9.3, Cary, NC, USA).

Results
=======

A total of 2284 persons met all the criteria to be included as COPD patients for this study. Their mean (±standard deviation) age was 70.3 ± 9.8 years, and 52.5% were women. A total of 1412 patients were matched to three controls, 851 could be matched to only two controls, and 21 patients could be matched to only one control. Only three COPD patients could not be matched to a control, and were thus excluded from this analysis.

COPD patients were significantly more likely than their controls to have a diagnosis of renal or urinary tract disease ([Table 1](#t1-copd-8-127){ref-type="table"}). A total of 714 COPD patients had 827 different renal or urinary tract diagnoses, as compared with 1260 control patients with 1494 diagnoses. Chronic renal failure was more than three times more prevalent among COPD patients (2.89%) than among controls (0.79%). Acute renal failure was also significantly more common among COPD patients (1.40%) than the controls (0.59%).

COPD patients did not have an increased prevalence of diagnosed liver parenchymal diseases (cirrhosis, hepatitis, or other chronic conditions, [Table 2](#t2-copd-8-127){ref-type="table"}). However, they did have a significantly increased prevalence of gallbladder disease (2.76% in COPD versus 1.63% of controls, *P* \< 0.001) and pancreatic disease (1.40% versus 0.60%, *P* \< 0.001).

COPD patients were significantly more likely to have renal or hepatic laboratory testing and more likely to have abnormal tests ([Table 3](#t3-copd-8-127){ref-type="table"}). Approximately 14% of the COPD patients had at least one abnormal liver function test and at least 29% had an abnormal renal test, versus 10% and 17% for their controls, respectively. We did not find a significant relationship between the prevalence of hepatic laboratory abnormalities and COPD complexity. Patients with high and moderate COPD complexity were more likely to have a blood urea nitrogen test that was more than twice the upper limit of normal (9.0%, 7.1%, and 5.0% for high, moderate, and low complexity, respectively, *P* \< 0.05). However, there was no significant correlation between COPD complexity and elevation in serum creatinine.

COPD patients had substantially more prescription medication fills, including those that are potentially harmful to the kidneys or liver ([Table 4](#t4-copd-8-127){ref-type="table"}). The greatest differences between COPD and controls in terms of potentially nephrotoxic drug exposure were seen in the central nervous system and electrolyte categories. In terms of potentially hepatotoxic drugs, the greatest differences were found in these same categories, plus antibiotics and anti-infective agents.

We did not find a significant correlation between COPD complexity and any of the specific hepatic or renal ICD-9 diagnoses (data not shown). The total number of prescription fills did vary by COPD complexity \[mean fills during the study period: low (145.9), moderate (178.6), and high (198.7), *P* \< 0.001\]. Correspondingly, the mean total number of fills for potentially nephrotoxic (15.0, 17.9, and 20.2) and hepatotoxic (23.2, 28.0, and 32.1) medications also increased by COPD complexity (*P* \< 0.01 for all differences).

Discussion
==========

We found that COPD patients had approximately twice the incidence of acute renal failure, and three times the prevalence of diagnosed chronic renal failure than did the age-matched and gender-matched controls. Elevations in renal function tests were also common: 27.1% of the COPD cohort had at least one abnormal creatinine level during the study period as compared with 16.7% of controls. Some of this difference may be attributable to exposure to potentially nephrotoxic medications in that COPD patients averaged 17.6 prescription fills for potentially nephrotoxic agents as opposed to 13.6 fills for controls. However, some of the difference in renal disease could be due to the higher prevalence of cardiovascular disease and other chronic medical conditions that we have already demonstrated in this COPD population.[@b2-copd-8-127],[@b4-copd-8-127]

We did not find an increased prevalence of diagnosed liver disease among COPD patients, but they were significantly more likely to have gallbladder disease or pancreatic disease. COPD patients did have a higher prevalence of abnormal liver function tests, with 12.1% having at least one abnormal aspartate aminotransferase test during the 3-year study period versus 6.9% of the controls. COPD patients were also significantly more likely to be treated with potentially hepatotoxic medications, with the average COPD patient receiving a mean 27.4 prescription fills for potentially hepatotoxic drugs versus 19.9 for the controls.

The significance of this study is that it demonstrates that renal diseases, as well as abnormal renal function tests, are relatively common among COPD patients in the general population. COPD patients also have increased liver enzyme abnormalities, gallbladder disease, and pancreatic disease, although the prevalence of diagnosed liver disease was not increased. These are potentially important considerations in the clinical management of all COPD patients, especially for those who may be initiating a new medication with potential hepatic or renal toxicity. Traditionally, renal function and hepatic disease testing are not standard components of COPD patient evaluation, and it is possible that a substantial number of renal and hepatic disease cases are undiagnosed. Therefore, if a patient does develop disease or laboratory abnormalities after initiation of a new treatment, it can be very difficult to know whether it is due to a previously undiagnosed chronic renal or hepatic condition, a side effect of the new medication, or some combination of both. Furthermore, COPD patients in our cohort had 59% more prescription fills overall, plus substantially more fills of known potentially nephrotoxic and hepatotoxic medications, so the potential for harmful medication interactions is also greater.

The results of pulmonary function tests were not available for this study, so we were not able to stratify the population by the severity of airflow obstruction or the newer GOLD (Global Initiative for Chronic Obstructive Lung Disease) staging system. We did stratify the COPD patients into thirds based on respiratory disease utilization, reasoning that persons with advanced COPD are more likely to have increased health care utilization. However, there were no significant associations between COPD complexity and diagnosed liver disease or elevated hepatic enzymes. We did review the medical records of all COPD patients with hepatic disease, and a history of alcohol abuse was documented in 25%. However, we were not able to examine the medical records of controls, so the significance of this finding is uncertain.

Other COPD cohort studies have found a high prevalence of comorbidities, but there are few that have specifically examined hepatic disease. A case-control analysis of 1388 Medicaid beneficiaries with COPD reported a higher prevalence of mild liver disease as compared with matched controls (2.95% versus. 1.59%; *P* \< 0.05), but the difference in moderate or severe liver disease did not reach statistical significance (0.79% versus 0.36%).[@b7-copd-8-127] In a large cohort of persons from the United Kingdom who were free of diagnosed hepatobiliary disease, higher levels of bilirubin were associated with a slightly lower risk of COPD (6% decrease in risk per 0.1 mg/dL increase in serum bilirubin level).[@b8-copd-8-127] In a study of 666 persons with chronic disease in Japan, 13.8% of those with chronic liver disease had undiagnosed airflow obstruction as compared with 9.0% of those who did not, yielding an odds ratio of 2.10 (95% confidence interval 1.23--3.57) after adjustment for age, gender, and smoking history.[@b9-copd-8-127] Another analysis of a small cohort of persons with chronic hepatitis C found evidence of accelerated decline in forced expiratory volume in one second and diffusing capacity of lung for carbon monoxide at a rate similar to that of smokers without hepatitis C, and additive affects on decline among those with hepatitis C who continued to smoke.[@b10-copd-8-127]

There is also scant published information on the association between COPD and renal disease. In a study of 508 current and ex-smokers who had detailed renal function studies, pulmonary function testing, and computed tomography scan analysis, there was a strong correlation between glomerular filtration rate and the extent of emphysema, but not percent predicted forced expiratory volume in one second or other measures of airflow obstruction.[@b11-copd-8-127] In a retrospective analysis of 3358 vascular surgery patients from The Netherlands, the prevalence of COPD was inversely related to kidney function, with COPD present in 47%, 38%, and 32% of patients with an estimated glomerular filtration rate \< 60, 60--89, and ≥90 mL/min/1.73 m[@b2-copd-8-127], respectively.[@b12-copd-8-127] In a study of 433 ambulatory COPD patients from Norway, the prevalence of undiagnosed chronic renal failure (glomerular filtration rate \< 60) was 9.6% in women and 5.1% in men.[@b13-copd-8-127] In a study of 288 hospitalized COPD patients from Italy, chronic renal failure was cited as a comorbidity in 26.3% of the cohort, but it was never cited as a primary cause for their admission.[@b14-copd-8-127]

This project has important limitations that should be noted. The greatest limitations are those that are common to all observational studies. In this cohort, all laboratory testing and labeling of patients with diagnoses is done solely at the discretion of their treating physician, and it is highly likely that there is great variability from physician to physician about when laboratory testing is obtained and how diagnoses are made. Some of this variability may explain the discrepancy between the relatively high prevalence of abnormal laboratory tests and low prevalence of diagnosed renal and hepatic disease. Data obtained from other cohorts where practice patterns are different may be expected to have different prevalences than we have observed. However, differences in practice patterns are unlikely to account fully for the substantial differences between the COPD and control cohorts. Similarly, they would not explain the substantial increase in dispensing of all drugs, including nephrotoxic and hepatotoxic agents, among COPD patients. Variability in patient's health care-seeking behavior may have also affected our results. For example, patients who are reticent about seeking medical attention could have few opportunities for the diagnosis of renal or hepatic abnormalities. Our cohorts were all members of one health plan in one geographic region, so financial barriers or regional variations in access to care should not have been major limitations. Finally, the association between COPD and renal or hepatic disease may be confounded by the high prevalence of other comorbidities, such as coronary artery disease and congestive heart failure, which have an increased prevalence among COPD patients.

COPD patients are at risk for a spectrum of comorbid complications, most importantly those other diseases that are also strongly related to cigarette smoking such as heart disease and cancer. Renal and hepatic abnormalities, while less obvious and typically more transient, may also be common and have important implications on new therapies. The potential for nephrotoxicity and hepatotoxicity should be kept in mind by clinicians treating patients with COPD when initiating new therapies and when considering the risk/benefit characteristics of pharmacologic interventions.
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###### 

Prevalence of renal disease in chronic obstructive pulmonary disease cases and controls

  Condition (ICD-9 code)                                                                                                            Cases (n = 2284)   Controls (n = 5959)   *P* value
  --------------------------------------------------------------------------------------------------------------------------------- ------------------ --------------------- -----------
  Total patients with any renal or urinary tract diagnosis (580--599.x; excluding 588)[\*](#tfn1-copd-8-127){ref-type="table-fn"}   714 (31.3)         1260 (21.1)           \<0.001
  Acute glomerulonephritis (580.x)                                                                                                  1 (0.04)           2 (0.03)              0.828
  Nephrotic syndrome (581.x)                                                                                                        6 (0.26)           4 (0.07)              0.022
  Chronic glomerulonephritis (582.x)                                                                                                1 (0.04)           1 (0.02)              0.481
  Nephritis and nephropathy (583.x)                                                                                                 26 (1.14)          46 (0.77)             0.110
  Acute renal failure (584.x)                                                                                                       32 (1.40)          35 (0.59)             \<0.001
  Chronic renal failure (585.x)                                                                                                     66 (2.89)          47 (0.79)             \<0.001
  Renal failure, unspecified (586)                                                                                                  25 (1.09)          26 (0.44)             \<0.001
  Renal sclerosis, unspecified (587)                                                                                                0 (0.00)           1 (0.02)              0.530
  Disorders secondary to renal disease (588)                                                                                        17 (0.74)          15 (0.25)             \<0.001
  Kidney infections (590.x)                                                                                                         7 (0.31)           8 (0.13)              0.101
  Hydronephrosis (591)                                                                                                              9 (0.39)           11 (0.18)             0.084
  Calculi of kidney and ureter (592.x)                                                                                              36 (1.58)          98 (1.64)             0.826
  Other disorders of ureter (593.x)                                                                                                 180 (7.88)         218 (3.66)            \<0.001
  Calculus of lower tract (594.x)                                                                                                   5 (0.22)           8 (0.13)              0.386
  Cystitis (595.x)                                                                                                                  9 (0.39)           15 (0.25)             0.283
  Other disorders of bladder (596.x)                                                                                                28 (1.23)          67 (1.12)             0.699
  Urethritis (597.x)                                                                                                                0 (0.00)           5 (0.08)              0.166
  Urethral stricture (598.x)                                                                                                        8 (0.35)           15 (0.25)             0.448
  Other disorders of the urinary tract (599.x)                                                                                      371 (16.2)         872 (14.6)            0.068
  Subtypes of 599.x                                                                                                                                                          
   599.0 urinary tract infection                                                                                                    297 (13.0)         702 (11.8)            0.128
   599.2 urethral diverticulum                                                                                                      1 (0.04)           1 (0.02)              0.481
   599.3 urethral caruncle                                                                                                          0 (0.00)           2 (0.03)              0.381
   599.4 urethral false passage                                                                                                     0 (0.00)           3 (0.05)              0.284
   599.6 urinary obstruction, NOS                                                                                                   6 (0.26)           3 (0.05)              0.009
   599.7 hematuria                                                                                                                  105 (4.60)         248 (4.16)            0.382
   599.8 other specified disorders                                                                                                  2 (0.09)           6 (0.10)              0.864
   599.9 other unspecified                                                                                                          5 (0.22)           8 (0.13)              0.386

**Notes:** ^\*^Patients may have more than one renal or urinary tract diagnosis. Values expressed as the number of patients and percent (cases/100) of the COPD or control cohort. Disease categories without a patient in either cohort were not listed.

**Abbreviation:** NOS, not otherwise specified.

###### 

Diagnosed hepatic, gallbladder, and pancreatic diseases among chronic obstructive pulmonary disease cases and controls

                                                                                                            Cases (n = 2284)   Controls (n = 5959)   *P* value
  --------------------------------------------------------------------------------------------------------- ------------------ --------------------- -----------
  Total patients with any hepatic diagnosis[\*](#tfn4-copd-8-127){ref-type="table-fn"} (070.x, 570−573.x)   25 (1.09)          66 (1.11)             0.96
  Viral hepatitis including hepatitis A, B, or C (070.x)                                                    10 (0.44)          30 (0.50)             0.67
  Acute and subacute hepatic necrosis (570.x)                                                               0 (0.00)           2 (0.03)              0.38
  Alcohol-related liver diseases (571.1−0.3)                                                                4 (0.18)           11 (0.18)             0.93
  Non-alcohol related liver diseases (571.4−0.9)                                                            10 (0.44)          32 (0.54)             0.57
  Abscess and other liver infections (572.0, 572.1, 573.1−573.3)                                            4 (0.18)           8 (0.13)              0.75
  All gallbladder disease including cholelithiasis (574.x−576.x)                                            63 (2.76)          97 (1.63)             \<0.001
  All pancreatic disease (577.x)                                                                            32 (1.40)          36 (0.60)             \<0.001

**Notes:** Values expressed as the number of patients and percent (cases/100) of the chronic obstructive pulmonary disease cases or controls.

Patients may have more than one specific hepatic diagnosis.

###### 

Prevalence of laboratory abnormalities among COPD cases and controls

  Test                                 No tests obtained                                        One or more tests-all normal                             One or more tests-at least one elevated
  -------------------------- --------- -------------------------------------------------------- -------------------------------------------------------- -------------------------------------------------------
  **Liver function tests**                                                                                                                               
  Alkaline phosphatase       COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}311 (13.6)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1659 (72.6)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}314 (13.7)
   (\>Upper limit nl)        Control   1292 (21.7)                                              4104 (68.9)                                              563 (9.45)
  Alkaline phosphatase       COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}311 (13.6)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1929 (84.5)   44 (1.9)
   (\>2 × Upper limit nl)    Control   1292 (21.7)                                              4572 (76.7)                                              95 (1.6)
  ALT (SGPT)                 COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}326 (14.3)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1757 (76.9)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}201 (8.8)
   (\>Upper limit nl)        Control   1227 (20.6)                                              4392 (73.7)                                              340 (5.7)
  ALT (SGPT)                 COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}326 (14.3)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1886 (82.6)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}72 (3.2)
   (\>2 × Upper limit nl)    Control   1227 (20.6)                                              4622 (77.6)                                              110 (1.8)
  AST (SGOT)                 COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}300 (13.1)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1707 (74.7)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}277 (12.1)
   (\>Upper limit nl)        Control   1235 (20.7)                                              4313 (72.4)                                              411 (6.90)
  AST (SGOT)                 COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}300 (13.1)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1880 (82.3)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}104 (4.5)
   (\>2 × Upper limit nl)    Control   1235 (20.7)                                              4563 (76.6)                                              161 (2.7)
  Total bilirubin            COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}308 (13.2)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1725 (75.5)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}251 (11.0)
   (\>Upper limit nl)        Control   1294 (21.7)                                              4165 (69.9)                                              500 (8.39)
  Total bilirubin            COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}308 (13.2)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1924 (84.2)   ^†^52 (2.3)
   (\>2 × Upper limit nl)    Control   1294 (21.7)                                              4575 (76.8)                                              90 (1.5)
  LDH                        COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}2132 (93.9)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}97 (4.2)      [\*](#tfn6-copd-8-127){ref-type="table-fn"}55 (2.4)
   (\>Upper limit nl)        Control   5779 (97.0)                                              124 (2.0)                                                56 (0.9)
  LDH                        COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}2132 (93.9)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}146 (6.4)     6 (0.2)
   (\>2 × Upper limit nl)    Control   5779 (97.0)                                              161 (2.7)                                                19 (0.3)
  Amylase                    COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}1410 (61.7)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}799 (35.0)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}75 (3.3)
   (\>Upper limit nl)        Control   4678 (78.5)                                              1187 (19.9)                                              94 (1.6)
  Amylase                    COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}1410 (61.7)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}848 (37.1)    26 (1.1)
   (\>2 × Upper limit nl)    Control   4678 (78.5)                                              1249 (20.9)                                              32 (0.5)
  **Renal function tests**                                                                                                                               
  Blood urea nitrogen        COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}237 (10.4)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1395 (61.1)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}652 (28.5)
   (\>Upper limit nl)        Control   1044 (17.5)                                              3970 (66.2)                                              945 (15.8)
  Blood urea nitrogen        COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}237 (10.4)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1895 (83.0)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}152 (6.7)
   (\>2 × Upper limit nl)    Control   1044 (17.5)                                              4762 (79.9)                                              153 (2.6)
  Creatinine                 COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}221 (9.68)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1445 (63.3)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}618 (27.1)
   (\>Upper limit nl)        Control   954 (16.0)                                               4008 (67.3)                                              997 (16.7)
  Creatinine                 COPD      [\*](#tfn6-copd-8-127){ref-type="table-fn"}221 (9.68)    [\*](#tfn6-copd-8-127){ref-type="table-fn"}1946 (85.2)   [\*](#tfn6-copd-8-127){ref-type="table-fn"}117 (5.1)
   (\>2 × Upper limit nl)    Control   954 (16.0)                                               4878 (81.9)                                              127 (2.1)

**Notes:** Values expressed as the number of patients and row percent of the COPD or control group.

Difference between COPD and control significant (*P* \< 0.01).

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; COPD, chronic obstructive pulmonary disease; ULN, upper limit of normal; LDH, lactate dehydrogenase; SGOT, serum glutamic oxaloacetic transaminase; SPGT, serum glutamic pyruvate transaminase.

###### 

Mean prescription fills during the three-year study period among chronic obstructive pulmonary disease cases and matched controls

                                             All drugs                                                Potentially nephrotoxic                                   Potentially hepatotoxic
  ------------------------------------------ -------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------
  Anti-infectives and antibiotics                                                                                                                               
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}8.7 (11.8)    [\*](#tfn9-copd-8-127){ref-type="table-fn"}2.4 (4.5)      [\*](#tfn9-copd-8-127){ref-type="table-fn"}6.3 (8.7)
   Control                                   5.1 (9.0)                                                1.6 (3.3)                                                 3.3 (6.0)
  Antineoplastics                                                                                                                                               
   COPD                                      0.9 (5.3)                                                0.3 (4.5)                                                 0.6 (4.4)
   Control                                   0.8 (5.2)                                                0.3 (3.3)                                                 0.5 (4.3)
  Autonomic agents                                                                                                                                              
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}20.4 (31.6)   0                                                         [^†^](#tfn10-copd-8-127){ref-type="table-fn"}0.5 (3.1)
   Control                                   2.6 (8.4)                                                0                                                         0.4 (2.6)
  Blood formation and anticoagulation                                                                                                                           
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}2.9 (11.0)    0                                                         [\*](#tfn9-copd-8-127){ref-type="table-fn"}1.2 (4.5)
   Control                                   1.5 (7.0)                                                0                                                         0.7 (3.4)
  Cardiovascular                                                                                                                                                
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}35.6 (49.4)   [\*](#tfn9-copd-8-127){ref-type="table-fn"}9.6 (17.4)     [\*](#tfn9-copd-8-127){ref-type="table-fn"}12.4 (23.9)
   Control                                   30.3 (45.9)                                              8.7 (17.3)                                                11.3 (22.6)
  Central nervous system agents                                                                                                                                 
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}32.7 (50.6)   [\*](#tfn9-copd-8-127){ref-type="table-fn"}11.3 (11.3)    [\*](#tfn9-copd-8-127){ref-type="table-fn"}12.4 (22.0)
   Control                                   18.8 (34.4)                                              8.2 (16.2)                                                7.6 (15.8)
  Electrolytic, caloric, and water balance                                                                                                                      
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}13.9 (25.9)   [\*](#tfn9-copd-8-127){ref-type="table-fn"}4.7 (8.6)      [\*](#tfn9-copd-8-127){ref-type="table-fn"}5.7 (14.0)
   Control                                   7.3 (18.3)                                               2.6 (6.4)                                                 2.1 (8.8)
  Gastrointestinal drugs                                                                                                                                        
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}8.1 (15.6)    [^†^](#tfn10-copd-8-127){ref-type="table-fn"}0.14 (1.9)   [\*](#tfn9-copd-8-127){ref-type="table-fn"}4.1 (10.5)
   Control                                   5.4 (13.4)                                               0.07 (1.7)                                                2.8 (9.2)
  Hormones (natural and synthetic)                                                                                                                              
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}23.1 (33.5)   0.03 (0.6)                                                [\*](#tfn9-copd-8-127){ref-type="table-fn"}4.5 (13.4)
   Control                                   17.6 (30.5)                                              0.01 (0.8)                                                4.9 (13.6)
  Unclassified therapeutics                                                                                                                                     
   COPD                                      6.5 (15.8)                                               0.1 (2.2)                                                 0
   Control                                   4.6 (13.0)                                               0.1 (2.7)                                                 0
  Eye, ear, nose, and throat preparations                                                                                                                       
   COPD                                      3.9 (10.1)                                               0                                                         0.10 (1.2)
   Control                                   3.7 (10.3)                                               0                                                         0.09 (0.9)
  Total                                                                                                                                                         
   COPD                                      [\*](#tfn9-copd-8-127){ref-type="table-fn"}169.6 (154)   [\*](#tfn9-copd-8-127){ref-type="table-fn"}17.6 (18.5)    [\*](#tfn9-copd-8-127){ref-type="table-fn"}27.4 (28.2)
   Control                                   106.7 (116)                                              13.6 (15.5)                                               19.9 (22.9)

**Notes:** Values expressed as the mean (standard deviation).

*P* \< 0.01;

*P* \< 0.05.

**Abbreviation:** COPD, chronic obstructive pulmonary disease.
